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Abstract
Background: Recently, circulating microRNAs (miRNAs) have been reported to be stably detectable in plasma/serum
and to function as potent biomarkers in various cancers. The aim of this study was to evaluate the expression
level of plasma miRNA-195 in patients with non-small cell lung cancer (NSCLC) and investigate its diagnostic and
prognostic value.
Methods: Quantitative real-time PCR was performed to evaluate plasma miRNA-195 levels in 100 NSCLC patients
and 100 healthy volunteers. The association between miRNA-195 expression and clinicopathological factors as well
as the overall survival was analyzed. Receiver-operating characteristic (ROC) curve analysis was carried out to assess
the potential value of plasma miRNA-195 for NSCLC diagnosis.
Results: Plasma miRNA-195 was downregulated in NSCLC patients compared with healthy controls (P < 0.001).
Decreased plasma miRNA-195 expression was significantly associated with lymph node metastasis and advanced
clinical stage. ROC curve analysis showed that plasma miRNA-195 was a useful marker for NSCLC diagnosis.
Multivariate Cox regression analysis confirmed low plasma miRNA-195 expression as an independent unfavorable
prognostic factor for NSCLC patients.
Conclusions: These findings indicate that plasma miRNA-195 might serve as a promising biomarker for the early
detection and prognosis evaluation of NSCLC.
Keywords: miRNAs, Biological markers, Non-small cell lung cancer, Diagnosis, Prognosis
Abbreviations: AUC, Area under the curve; miRNA, MicroRNA; NSCLC, Non-small cell lung cancer; ROC, Receiver-
operating characteristic; RR, Relative risk; RT-PCR, Reverse transcription-polymerase chain reaction
Background
Lung cancer is the leading cause of cancer deaths world-
wide, and non-small cell lung cancer (NSCLC) accounts
for nearly 85 % of all cases [1]. Despite recent advances
in experimental and clinical oncology, NSCLC is mostly
diagnosed in late stages and survival has not improved
significantly over several decades. To date, mechanisms
underlying NSCLC carcinogenesis and progression re-
main poorly understood. Therefore, it is urgent to eluci-
date the regulatory network underlying NSCLC and
develop novel biomarkers for its early diagnosis, accurate
assessment, targeted therapy, and prognosis evaluation.
MicroRNAs (miRNAs) are short (about 22 nucleotides
in length), highly conserved small non-coding RNA
molecules that negatively regulate gene expression by
binding to target messenger RNAs (mRNAs) at their 3′-
untranslated region, leading to mRNA degradation or
translation suppression [2]. Deregulation of miRNA ex-
pression has been identified in many human diseases, in-
cluding cancers. Some highly expressed miRNAs could
function as oncogenes by repressing tumor suppressor
genes, whereas low-expressed miRNAs could function as
tumor suppressors by negatively regulating oncogenes.
Emerging evidence suggests that miRNAs act as key reg-
ulators in a wide variety of biological processes that
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contribute to tumorigenesis and development, such as
tumor cell differentiation, proliferation, apoptosis, inva-
sion, angiogenesis, and epithelial mesenchymal transition
[3–5]. Since circulating miRNAs are well protected from
RNase digestions and highly stable in plasma/serum [6],
they have been regarded as novel potential biomarkers
in cancer detection and monitoring. For example, serum
miR-30e and miR-223 are useful diagnostic biomarkers
for hepatocellular carcinoma [7]. Serum miR-200c ex-
pression correlates with overall survival of patients with
gastric cancer [8]. Serum expression levels of miR-17,
miR-21, and miR-92 predict recurrence after adjuvant
chemotherapy in colon cancer patients [9]. Serum miR-
183 can be used to predict the response of renal cell car-
cinoma cells to the cytotoxicity induced by natural killer
cells [10]. However, the use of circulating miRNAs as
blood-based, minimally invasive biomarkers in NSCLC
is still relatively less explored.
miR-195 is located at chromosome 17p13.1, a region
that is frequently deleted in human cancers. Extensive
researches have suggested decreased miRNA-195 ex-
pression and its tumor suppressive function in various
solid tumors, including glioblastoma [11], thyroid cancer
[12], tongue squamous cell carcinoma [13], esophageal
squamous cell carcinoma [14], gastric cancer [15], colo-
rectal cancer [16], hepatocellular carcinoma [17], pros-
tate cancer [18], cervical cancer [19], bladder cancer
[20], and osteosarcoma [21]. Circulating miR-195 has
been identified as a potential marker for the detection
and/or prognosis evaluation of adrenocortical cancer [22],
breast cancer [23], cervical cancer [24], and osteosarcoma
[25]. In patients with NSCLC, tissue miRNA-195 expres-
sion was downregulated, and its downregulation was cor-
related with shorter overall survival [26]. However, the
diagnostic and prognostic value of plasma miRNA-195 in
NSCLC patients remains unknown. In the present study,
we investigated plasma miRNA-195 levels in patients with
NSCLC and evaluated its association with clinicopatho-
logical features and survival time.
Methods
Patient samples
A total of 100 primary NSCLC patients who received
radical excision at The Fourth People’s Hospital of Jinan
and The Central Hospital of Jinan between January 2008
and December 2010 were included in this study. Periph-
eral blood samples (5 ml) were obtained at the time of
diagnosis. Cell-free plasma was isolated from blood sam-
ples within 12 h after collection using a two-step proto-
col (1500 r.p.m. for 10 min, 12,000 r.p.m. for 2 min) to
prevent contamination by cellular nucleic acids and then
stored at −80 °C until further processing. Blood samples
from 100 healthy volunteers were used as control. None
of the NSCLC patients had received chemotherapy or
radiotherapy prior to blood sampling. A summary of the
baseline characteristics of NSCLC cases and healthy con-
trols is presented in Table 1. Follow-up data for all NSCLC
patients were acquired, and the survival time was calcu-
lated from the date of diagnosis to the date of death or last
follow-up. Written informed consent was obtained from
all participants, and research protocols were approved by
the Ethical Committee of The Fourth People’s Hospital of
Jinan and The Central Hospital of Jinan.
MicroRNA isolation and RT-PCR assay
Total RNA was extracted from 400 μL of plasma samples
using a miRVana PARIS Kit (Ambion, Austin, TX, USA)
and eluted into 100 μL of pre-heated (95 °C) Elution
Solution according to the manufacturer’s instructions.
Reverse-transcription was carried out with the TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosys-
tems) in 15 μL containing 5 μL of RNA extract, 0.15 μL of
100 mM dNTPs, 1 μL of Multiscribe Reverse Transcript-
ase (50 U/μL), 1.5 μL of 10× Reverse Transcription Buffer,
0.19 μL of RNase inhibitor (20 U/μL), 1 μL of gene-
specific primer, and 6.16 μL of nuclease-free water. Then,
1.33 μL of complementary DNA (cDNA) solution was
Table 1 Clinicopathological characteristics of non-small cell
lung cancer patients and healthy controls
Clinical characteristic NSCLC (n = 100) Control (n = 100) P
Age
<60 49(51.6 %) 46(48.4 %) 0.706
≥60 51(48.6 %) 54(51.4 %)
Gender
Male 65(48.1 %) 70(51.9 %) 0.538
Female 35(53.8 %) 30(46.2 %)
Smoking status
Current 32(45.7 %) 38(54.3 %) 0.624
Former 53(52.5 %) 48(47.5 %)
Never 15(51.7 %) 14(48.3 %)
TNM stage
Stages I–II 57 – –
Stage III 43 – –
Differentiation
G1 + G2 55 – –
G3 45 – –
Lymph node metastasis
Negative 37 – –
Positive 63 – –
Histological type
Adenocarcinoma 44 – –
Squamous carcinoma 46 – –
Others 10 – –
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amplified using 10 μL of TaqMan 2× Universal PCR
Master Mix with no AmpErase UNG (Applied Biosys-
tems), 1 μL of gene-specific primer, and 7.67 μL of
nuclease-free water in a final volume of 20 μL. Quanti-
tative PCR was run on a 7300 Real-Time PCR system
(Applied Biosystems), and the reaction mixtures were
incubated at 95 °C for 10 min, followed by 40 cycles of
95 °C for 15 s and 60 °C for 1 min. Relative quantifica-
tion of miRNA-195 expression was calculated with the
2−ΔCt method. Due to the lack of universal endogenous
controls for plasma samples, synthetic cel-miR-39 was
spiked into each sample as an internal control as previ-
ously described [6, 27].
Statistics
Statistical analyses were carried out using SPSS version
17.0 (SPSS Inc., Chicago, IL, USA) or MedCalc 9.3.9.0
(MedCalc, Mariakerke, Belgium) software. P values <0.05
were considered statistically significant. The Mann-Whitney
U test was performed to compare the expression level of
plasma miRNA-195 between NSCLC patients and healthy
controls. Associations between clinicopathological pa-
rameters and plasma miRNA-195 expression were
evaluated using chi-square test. Survival curves were
constructed with the Kaplan-Meier method and com-
pared by log-rank tests. Cox regression analysis was
performed to analyze prognostic significance of each
variable. Receiver-operating characteristic (ROC) curve
was constructed, and the area under the curve (AUC)
was calculated to assess the potential value of plasma
miRNA-195 for NSCLC diagnosis.
Results
Decreased plasma miRNA-195 in NSCLC patients and its
diagnostic value
Plasma miRNA-195 levels in 100 NSCLC patients and 100
healthy controls were detected by reverse transcription-
polymerase chain reaction (RT-PCR). The results showed
that plasma miRNA-195 was significantly downregulated
in NSCLC patients compared to healthy controls (P <
0.01, Fig. 1). In addition, when all NSCLC patients were
grouped based on TNM stage, miRNA-195 expression
levels were significantly lower in stage III patients than
those in stage I or II patients (both P < 0.01, Fig. 1). The
median expression level of miRNA-195 was used as a cut-
off point to divide all the 100 patients into two groups:
high miRNA-195a expression group (n = 50) and low
miRNA-195 expression group (n = 50).
ROC curve analysis showed that plasma miRNA-195
was a useful marker for discriminating NSCLC patients
from healthy controls, with the AUC value of 0.89 (95 %
CI, 0.82–0.95; Fig. 2). The optimal sensitivity and specifi-
city were 78 and 86 %, respectively.
Plasma miRNA-195 correlates with clinicopathological
features of NSCLC
Table 2 displays the associations between plasma miRNA-
195 expression and the clinicopathological features. Low
plasma miRNA-195 levels were significantly associated
with higher incidence of lymph node metastasis (P =
0.002) and advanced clinical stage (P < 0.001) but not with
patient’s age, gender, histological type, tumor grade, and
tumor size.
Plasma miRNA-195 correlates with patient’s prognosis
Using the Kaplan-Meier method and log-rank test, we
found that the overall survival of NSCLC patients with
low plasma miRNA-195 levels was significantly shorter
than those with high plasma miRNA-195 levels (P < 0.001;
Fig. 3). Besides, the survival benefits were also found in
those with well tumor differentiation (P = 0.038), negative
Fig. 1 miRNA-195 expression levels in plasma samples of healthy
controls and different tumor node metastasis (TNM) stages (I, II, and
III) of non-small cell lung cancer (NSCLC) patients. Mann-Whitney U
test was used to determine statistical significance. The upper and
lower limits of the boxes and the lines inside the boxes indicate the
75th and 25th percentiles and the median, respectively. The whisker
caps indicate the 90th and 10th percentiles. *P < 0.01
Fig. 2 Receiver-operating characteristic (ROC) curve analysis of the
plasma miRNA-195 to detect non-small cell lung cancer patients
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lymph node metastasis (P = 0.011), and early TNM stage
(P < 0.001). Multivariate Cox regression analysis enrol-
ling abovementioned significant parameters revealed
that plasma miRNA-195 expression (relative risk (RR)
4.225; P = 0.016), lymph node status (RR 3.368; P = 0.035),
and clinical stage (RR 6.587; P = 0.002) were independent
prognostic markers for NSCLC patients (Table 3).
Discussion
Up to now, the exact mechanisms underlying NSCLC
are not fully understood. The discovery of miRNAs has
broadened our understanding of carcinogenesis. In terms
of NSCLC, abnormal expression of several miRNAs and
their function has been reported. For example, miRNA-
1290 showed increased expression in NSCLC tissues,
and its upregulation was correlated with positive lymph
node metastasis and advanced clinical stage [28]. Low
expression of miRNA-345 and miRNA-34a predicted
shorter overall survival of NSCLC patients [29, 30]. De-
creased serum miRNA-499 may serve as a novel diag-
nostic biomarker for NSCLC [31]. Ectopic expression of
miRNA-124 reduced lung cancer cell proliferation, inva-
sion, and migration [32]. Thus, functional miRNAs may
be applied for NSCLC diagnosis and prognosis and also
act as potential novel therapeutic targets.
Although many miRNAs are expressed in tissues and
tumor cells, their development as biomarkers requires
tissue collection by invasive methods as opposed to the
more convenient approach of studying peripheral blood.
Table 2 Correlation between plasma miRNA-195 expression and
different clinicopathological features in patients with non-small
cell lung cancer
Clinicopathological features No. of
cases
Plasma miR-195 expression P
Low (n, %) High (n, %)
Age
<60 49 22(44.0 %) 27(66.0 %) 0.322
≥60 51 28(54.9 %) 23(45.1 %)
Gender
Male 65 34(52.3 %) 31(47.7 %) 0.338
Female 35 16(45.7 %) 19(54.3 %)
Histological type
Squamous cell carcinoma 46 25(54.3 %) 21(45.7 %) 0.701
Adenocarcinoma 44 20(45.5 %) 24(54.5 %)
Others 10 5(50.0 %) 5(50.0 %)
Histological grade
G1 + G2 55 26(47.3 %) 29(52.7 %) 0.688
G3 45 24(53.3 %) 21(46.7 %)
Tumor size
≤3 cm 38 16(42.1 %) 22(57.9 %) 0.151
>3 cm 62 34(54.8 %) 28(45.2 %)
N classification
Positive 63 39(61.9 %) 24(28.1 %) 0.002
Negative 37 11(29.7 %) 26(70.3 %)
TNM stage
I + II 57 17(29.8 %) 40(70.2 %) <0.001
III 43 33(76.7 %) 10(23.3 %)
Fig. 3 Kaplan-Meier survival curves of non-small cell lung cancer
patients based on plasma miRNA-195 expression level. Low plasma
miRNA-195 expression level was significantly associated with poor
prognosis (P < 0.001, log-rank test)
Table 3 Univariate and multivariate analysis of overall survival in








Age at diagnosis (years)
<60 vs ≥60 0.56 – –
Gender






(G1 + G2) vs G3 0.038 0.085 1.054
Tumor size
≤3 vs >3 cm 0.13 – –
N classification
Positive vs negative 0.011 0.035 3.368
TNM stage
I–II vs III <0.001 0.002 6.587
Plasma miRNA-195
High vs low <0.001 0.016 4.225
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The stability and easy detectability make circulating
miRNAs an ideal candidate to serve as a biomarker for
cancer detection. In this study, we showed decreased
plasma miRNA-195 levels in NSCLC patients compared
with healthy controls. Downregulation of plasma miRNA-
195 was correlated with lymphatic metastasis and ad-
vanced TNM stage. ROC curve analysis revealed that
plasma miRNA-195 had a moderate diagnostic value for
NSCLC. Moreover, multivariate analysis confirmed plasma
miRNA-195 expression as an independent prognostic fac-
tor for NSCLC patients. These results suggest that plasma
miRNA-195 may serve as a useful diagnostic and prognos-
tic biomarker for NSCLC.
Our results are consistent with previous findings.
Zhang et al. identified circulating miRNA-195 as a diag-
nostic biomarker for the early detection of cervical can-
cer [24]. Cai et al. showed the association between
decreased serum miRNA-195 expression and positive
distant metastasis, advanced clinical stage, and poor
overall survival and disease-free survival in human
osteosarcoma [25]. In addition, serum miRNA-195 was
predictive of recurrence risk in adrenocortical cancer pa-
tients [22]. In patients with breast cancer, serum
miRNA-195 had a higher sensitivity for detecting tumor
response to neoadjuvant chemotherapy than conventional
tumor markers such as CEA and CA153. The potential
diagnostic and prognostic value of blood miRNA-195 in
other human malignancies would be an interesting and
important topic of future investigations.
Recently, Zhao et al. showed upregulation of miRNA-
195 expression in tumor tissues and plasma of NSCLC
patients and reported that there was no significant asso-
ciation between plasma miRNA-195 level and patient
survival [33]. These results are surprising because de-
creased miRNA-195 expression has been reported in
many human cancers including NSCLC. Zhou et al.
demonstrated miRNA-195 downregulation in NSCLC
samples and cell lines [34]. Liu et al. confirmed de-
creased miRNA-195 expression in NSCLC tumor tissues
and its association with poor survival [26]. In vitro and
in vivo functional assays revealed that miRNA-195 over-
expression suppressed NSCLC growth, migration, and
invasion [26, 34]. We suggest further studies with larger
sample size to clarify miRNA-195 expression and its
clinical and prognostic significance in NSCLC.
It is now clear that miRNAs exhibit oncogenic or
tumor suppressive properties by regulation of target
gene expression. MicroRNA-195 inhibits proliferation,
invasion, and metastasis in breast cancer cells by tar-
geting FASN, HMGCR, ACACA, and CYP27B1 [35].
MicroRNA-195 suppresses glucose uptake and prolifera-
tion of human bladder cancer cells by regulating GLUT3
expression [36]. MicroRNA-195 promotes apoptosis and
suppresses tumorigenicity of human colorectal cancer
cells by downregulating Bcl-2 [37]. In NSCLC, MYB and
CHEK1 have been confirmed as direct targets of
miRNA-195 [26, 34]. Previous studies have confirmed
that there is no “one-to-one” connection between miR-
NAs and target mRNAs. An average miRNA can have
more than 100 targets [38]. Conversely, several miRNAs
can converge on a single transcript target. Thus, the po-
tential regulatory circuitry afforded by miRNA-195 may
be enormous, and the accurate molecular mechanisms
on how miRNA-195 mediates NSCLC carcinogenesis
and development need further clarification.
Conclusions
In summary, the current study showed that the level of
plasma miRNA-195 was downregulated in NSCLC pa-
tients and associated with aggressive clinicopathological
characteristics. More importantly, decreased plasma
miRNA-195 could distinguish NSCLC from healthy con-
trol and predict poor patient survival. Based on these
results, plasma miRNA-195 might serve as a reliable
minimally invasive biomarker for early detection and
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